Efficacy and safety of Glecaprevir/Pibrentasvir plus Ribavirin in Patients who failed Direct-acting antivirals; DAAs with chronic hepatitis C
Latest Information Update: 27 Mar 2019
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 27 Mar 2019 New trial record